sacubitril
Sign in to saveSacubitril (; INN) is an antihypertensive drug used in combination with valsartan. The combination drug sacubitril/valsartan, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. It was approved under the FDA's priority review process for use in heart failure on July 7, 2015.
Key facts
- Drug.IUPAC_name
- 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid
- Drug.image
- Sacubitril skeletal.svg
- Drug.image_class
- skin-invert-image
- Drug.licence_EU
- yes
- Drug.CAS_number
- 149709-62-6
- Drug.UNII
- 17ERJ0MKGI
- Drug.ATCvet
- 149709-62-6
- Drug.ATC_prefix
- C09
- Drug.ATC_suffix
- DX04
- Drug.ATC_supplemental
- (combination with valsartan)
- Drug.PubChem
- 9811834
- Drug.DrugBank
- DB09292
- Drug.ChemSpiderID
- 7987587
- Drug.KEGG
- D10225
- Drug.synonyms
- AHU-377
- Drug.C
- 24
- Drug.H
- 29
- Drug.N
- 1
via Wikipedia infobox
Article
5 sectionsContents
- Side effects
- Mechanism of action
- Synthesis
- See also
- References
{{Infobox drug | drug_name = | IUPAC_name = 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid | image = Sacubitril skeletal.svg | image_class = skin-invert-image | alt = | caption =
| tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | licence_EU = yes | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =